Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Centre Leon Berard
Masonic Cancer Center, University of Minnesota
Life University
University of Pittsburgh
Columbia University
University of Southern California
Stanford University
Weill Medical College of Cornell University
University of Texas Southwestern Medical Center
JS InnoPharm, LLC
Cancer Research UK
SynerGene Therapeutics, Inc.
Northwell Health
Dushu Lake Hospital Affiliated to Soochow University
Dosentrx Ltd.
Laser LabCorp
Anaeropharma Science, Inc.
Tetra Bio-Pharma
The Clatterbridge Cancer Centre NHS Foundation Trust
University of Basel
Oshadi Drug Administration
Hospital General Universitario Gregorio Marañon
Roger Williams Medical Center
Humanigen, Inc.
GlaxoSmithKline
Herlev Hospital
Envita Medical Center, Inc.
Seattle Children's Hospital
Eisai Inc.
Synta Pharmaceuticals Corp.
Eisai Inc.
Adherex Technologies, Inc.
Exelixis
PRAECIS Pharmaceuticals Inc.